Hematopoietic and Lymphoid Cell NeoplasmDiRECTNCT05364086
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
An observational study of Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, run by University of Rochester NCORP Research Base at 259 sites in United States.
Trial summary
This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- What is being tested?
- Biospecimen Collection, Electronic Health Record Review and Interview
- Type of treatment
- Injection or infusion, Surgery or procedure
- How many people
- 2,100 participants
- Where
- 259 sitesUnited States
- Study dates
- 26 Apr 2022to 31 Jan 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: African American or European American patients diagnosed with stage I-IV invasive cancer receiving immune checkpoint inhibitor treatment
Who may be able to join
- Be 18 years of age or older
- Self-identify as African/African American/black (AA), or European American/ Caucasian/white (EA)
- Patients may identify a Hispanic/Latino ethnicity in combination with an AA or EA racial identity
- Have a current diagnosis of invasive cancer at stage I-IV
- Patients may have a history of previous cancer diagnosis and cancer treatment not involving immunotherapy
- Be scheduled to receive anti-PD-1/-L1 ICI-containing therapy alone or in combination with co-treatments (including alternative ICIs)
- Be able to speak and read English or Spanish
- Be able to provide informed consent
Who cannot join
- Identify as Asian, Pacific Islander, or American Indian/Alaskan Native
- Be diagnosed with melanoma (because melanoma is very rare in AAs)
- Currently participate in any trials of a cancer therapeutic nature; participation in noninterventional trial, or trials of symptom control or supportive nature is allowed; participation in future cancer therapeutic trials after completing the A2 assessment (e.g., after the second infusion of ICIs) is also allowed
- Have received prior immunotherapy for cancer, including checkpoint inhibitors, chimeric antigen receptor (CAR)-T therapy, cytokine therapy, and/or Bacillus Calmette-Guerin (BCG) for bladder cancer
Trial locations and contacts
259 sites in 1 country.
259 sites in 1 country
United States259 sites
Christus Saint Frances Cabrini Hospital
Alexandria, Louisiana, 71301
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
OSF Saint Anthony's Health Center
Alton, Illinois, 62002
Kaiser Permanente-Anaheim
Anaheim, California, 92806
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor, Michigan, 48106
Kaiser Permanente-Deer Valley Medical Center
Antioch, California, 94531
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911
Ascension Saint Elizabeth Hospital
Appleton, Wisconsin, 54915
AdventHealth Infusion Center Asheville
Asheville, North Carolina, 28803
Northside Hospital
Atlanta, Georgia, 30342
Augusta University Medical Center
Augusta, Georgia, 30912
Kaiser Permanente-Baldwin Park
Baldwin Park, California, 91706
LSU Health Baton Rouge-North Clinic
Baton Rouge, Louisiana, 70805
Our Lady of the Lake Physician Group
Baton Rouge, Louisiana, 70808
Louisiana Hematology Oncology Associates LLC
Baton Rouge, Louisiana, 70809
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
MBP Cancer Center - Baton Rouge General
Baton Rouge, Louisiana, 70809
Medical Center of Baton Rouge
Baton Rouge, Louisiana, 70816
Louisiana Hematology Oncology Associates
Baton Rouge, Louisiana, 70817
Our Lady of the Lake Medical Oncology
Baton Rouge, Louisiana, 70817
Ochsner High Grove
Baton Rouge, Louisiana, 70836
Beaufort Memorial Hospital
Beaufort, South Carolina, 29902
Indu and Raj Soin Medical Center
Beavercreek, Ohio, 45431
Kaiser Permanente-Bellflower
Bellflower, California, 90706
ThedaCare Cancer Care - Berlin
Berlin, Wisconsin, 54923
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Saint Joseph's/Candler - Bluffton Campus
Bluffton, South Carolina, 29910
Prisma Health Cancer Institute - Spartanburg
Boiling Springs, South Carolina, 29316
Trinity Health Medical Center - Brighton
Brighton, Michigan, 48114
Ascension Southeast Wisconsin Hospital - Elmbrook Campus
Brookfield, Wisconsin, 53045
Roswell Park Cancer Institute
Buffalo, New York, 14263
Minnesota Oncology - Burnsville
Burnsville, Minnesota, 55337
Illinois CancerCare-Canton
Canton, Illinois, 61520
Trinity Health Medical Center - Canton
Canton, Michigan, 48188
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
SIH Cancer Institute
Carterville, Illinois, 62918
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Centralia Oncology Clinic
Centralia, Illinois, 62801
Medical University of South Carolina
Charleston, South Carolina, 29425
Chelsea Hospital
Chelsea, Michigan, 48118
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, 60612
Ascension Calumet Hospital
Chilton, Wisconsin, 53014
AdventHealth Infusion Center Haywood
Clyde, North Carolina, 28721
Baptist Memorial Hospital and Cancer Center-Collierville
Collierville, Tennessee, 38017
John B Amos Cancer Center
Columbus, Georgia, 31904
Baptist Memorial Hospital and Cancer Center-Golden Triangle
Columbus, Mississippi, 39705
Mercy Hospital
Coon Rapids, Minnesota, 55433
Mary Bird Perkins Cancer Center - Covington
Covington, Louisiana, 70433
Northshore Oncology Associates-Covington
Covington, Louisiana, 70433
Ochsner Hematology Oncology North Shore - Covington (West Region)
Covington, Louisiana, 70433
Carle at The Riverfront
Danville, Illinois, 61832
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Kaiser Permanente-Franklin
Denver, Colorado, 80205
Illinois CancerCare-Dixon
Dixon, Illinois, 61021
Kaiser Permanente Dublin
Dublin, California, 94568
Northside Hospital - Duluth
Duluth, Georgia, 30096
Prisma Health Cancer Institute - Easley
Easley, South Carolina, 29640
HSHS Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Fairview Southdale Hospital
Edina, Minnesota, 55435
Crossroads Cancer Center
Effingham, Illinois, 62401
Christiana Care - Union Hospital
Elkton, Maryland, 21921
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Parkland Health Center - Farmington
Farmington, Missouri, 63640
Armes Family Cancer Center
Findlay, Ohio, 45840
Cancer Hematology Centers - Flint
Flint, Michigan, 48503
Genesee Hematology Oncology PC
Flint, Michigan, 48503
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Kaiser Permanente-Fontana
Fontana, California, 92335
Dayton Physicians LLC-Atrium
Franklin, Ohio, 45005
Ascension Saint Francis - Reiman Cancer Center
Franklin, Wisconsin, 53132
Kaiser Permanente-Fremont
Fremont, California, 94538
Kaiser Permanente-Fresno
Fresno, California, 93720
Unity Hospital
Fridley, Minnesota, 55432
Gibbs Cancer Center-Gaffney
Gaffney, South Carolina, 29341
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Central Care Cancer Center - Garden City
Garden City, Kansas, 67846
CaroMont Regional Medical Center
Gastonia, North Carolina, 28054
Tidelands Georgetown Memorial Hospital
Georgetown, South Carolina, 29440
Waccamaw Oncology - Georgetown
Georgetown, South Carolina, 29440
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids, Michigan, 49503
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Saint Francis Hospital
Greenville, South Carolina, 29601
Prisma Health Cancer Institute - Butternut
Greenville, South Carolina, 29605
Prisma Health Cancer Institute - Faris
Greenville, South Carolina, 29605
Saint Francis Cancer Center
Greenville, South Carolina, 29607
Prisma Health Cancer Institute - Eastside
Greenville, South Carolina, 29615
Self Regional Healthcare
Greenwood, South Carolina, 29646
Prisma Health Cancer Institute - Greer
Greer, South Carolina, 29650
Gibbs Cancer Center-Pelham
Greer, South Carolina, 29651
Baptist Cancer Center-Grenada
Grenada, Mississippi, 38901
Gulfport Memorial Hospital
Gulfport, Mississippi, 39502
Kaiser Permanente South Bay
Harbor City, California, 90710
HaysMed
Hays, Kansas, 67601
Comprehensive Cancer Centers of Nevada - Henderson
Henderson, Nevada, 89052
OptumCare Cancer Care at Seven Hills
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada-Southeast Henderson
Henderson, Nevada, 89074
Urology Specialists of Nevada - Green Valley
Henderson, Nevada, 89074
AdventHealth Hendersonville
Hendersonville, North Carolina, 28792
South Carolina Cancer Specialists PC
Hilton Head Island, South Carolina, 29926-3827
Kaiser Permanente Moanalua Medical Center
Honolulu, Hawaii, 96819
Terrebonne General Medical Center
Houma, Louisiana, 70360
Kaiser Permanente-Irvine
Irvine, California, 92618
Jackson Oncology Associates PLLC
Jackson, Mississippi, 39202
Mississippi Baptist Medical Center
Jackson, Mississippi, 39202
MU Health Care Goldschmidt Cancer Center
Jefferson City, Missouri, 65109
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas, 72401
Freeman Health System
Joplin, Missouri, 64804
University Health Truman Medical Center
Kansas City, Missouri, 64108
University of Kansas Cancer Center - North
Kansas City, Missouri, 64154
Ochsner Medical Center Kenner
Kenner, Louisiana, 70065
Kettering Medical Center
Kettering, Ohio, 45429
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Kaiser Permanente-Rock Creek
Lafayette, Colorado, 80026
Cancer Center of Acadiana
Lafayette, Louisiana, 70503
OptumCare Cancer Care at Charleston
Las Vegas, Nevada, 89102
Urology Specialists of Nevada - Southwest
Las Vegas, Nevada, 89113
Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas, Nevada, 89128
OptumCare Cancer Care at MountainView
Las Vegas, Nevada, 89128
Urology Specialists of Nevada - Northwest
Las Vegas, Nevada, 89128
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
Las Vegas, Nevada, 89135
Comprehensive Cancer Centers of Nevada - Town Center
Las Vegas, Nevada, 89144
Comprehensive Cancer Centers of Nevada-Summerlin
Las Vegas, Nevada, 89144
Summerlin Hospital Medical Center
Las Vegas, Nevada, 89144
OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada, 89169
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Northside Hospital - Gwinnett
Lawrenceville, Georgia, 30046
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan, 48154
Kaiser Permanente-Lone Tree
Lone Tree, Colorado, 80124
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027
Kaiser Permanente West Los Angeles
Los Angeles, California, 90034
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Fairview Clinics and Surgery Center Maple Grove
Maple Grove, Minnesota, 55369
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
West Jefferson Medical Center
Marrero, Louisiana, 70072
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Bon Secours Memorial Regional Medical Center
Mechanicsville, Virginia, 23116
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennessee, 38120
Ascension Columbia Saint Mary's Hospital Ozaukee
Mequon, Wisconsin, 53097
Bon Secours Westchester Emergency Center
Midlothian, Virginia, 23113
Bon Secours Saint Francis Medical Center
Midlothian, Virginia, 23114
Beebe South Coastal Health Campus
Millville, Delaware, 19967
Ascension Columbia Saint Mary's Hospital - Milwaukee
Milwaukee, Wisconsin, 53211
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Kaiser Permanente-Modesto
Modesto, California, 95356
Ochsner LSU Health Monroe Medical Center
Monroe, Louisiana, 71202
Monticello Cancer Center
Monticello, Minnesota, 55362
Waccamaw Oncology-Murrells Inlet
Murrells Inlet, South Carolina, 29576
Trinity Health Muskegon Hospital
Muskegon, Michigan, 49444
Waccamaw Oncology-Myrtle Beach
Myrtle Beach, South Carolina, 29577
ThedaCare Regional Medical Center - Neenah
Neenah, Wisconsin, 54956
Baptist Memorial Hospital and Cancer Center-Union County
New Albany, Mississippi, 38652
CarolinaEast Medical Center
New Bern, North Carolina, 28561
ThedaCare Cancer Care - New London
New London, Wisconsin, 54961
University Medical Center New Orleans
New Orleans, Louisiana, 70112
Ochsner Baptist Medical Center
New Orleans, Louisiana, 70115
Ochsner Medical Center Jefferson
New Orleans, Louisiana, 70121
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
New Ulm Medical Center
New Ulm, Minnesota, 56073
Helen F Graham Cancer Center
Newark, Delaware, 19713
Medical Oncology Hematology Consultants PA
Newark, Delaware, 19713
Christiana Care Health System-Christiana Hospital
Newark, Delaware, 19718
Providence Newberg Medical Center
Newberg, Oregon, 97132
University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri, 64116
Cancer and Hematology Centers of Western Michigan - Norton Shores
Norton Shores, Michigan, 49444
Cancer Care Center of O'Fallon
O'Fallon, Illinois, 62269
Kaiser Permanente-Oakland
Oakland, California, 94611
Beaufort Memorial/New River Cancer Center
Okatie, South Carolina, 29909
Mercy Hospital Oklahoma City
Oklahoma City, Oklahoma, 73120
The University of Kansas Cancer Center - Olathe
Olathe, Kansas, 66061
Kaiser Permanente-Ontario
Ontario, California, 91761
Ascension Mercy Hospital
Oshkosh, Wisconsin, 54904
ThedaCare Cancer Care - Oshkosh
Oshkosh, Wisconsin, 54904
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, 66210
Baptist Memorial Hospital and Cancer Center-Oxford
Oxford, Mississippi, 38655
Kaiser Permanente - Panorama City
Panorama City, California, 91402
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
Illinois CancerCare-Peru
Peru, Illinois, 61354
FirstHealth of the Carolinas-Moore Regional Hospital
Pinehurst, North Carolina, 28374
Trinity Health Saint Joseph Mercy Oakland Hospital
Pontiac, Michigan, 48341
Providence Portland Medical Center
Portland, Oregon, 97213
Providence Saint Vincent Medical Center
Portland, Oregon, 97225
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
Ascension All Saints Hospital
Racine, Wisconsin, 53405
Kaiser Permanente- Marshall Medical Offices
Redwood City, California, 94063
Corewell Health Reed City Hospital
Reed City, Michigan, 49677
Beebe Health Campus
Rehoboth Beach, Delaware, 19971
Valley Medical Center
Renton, Washington, 98055
Kaiser Permanente-Richmond
Richmond, California, 94801
Bon Secours Saint Mary's Hospital
Richmond, Virginia, 23226
Bon Secours Cancer Institute at Reynolds Crossing
Richmond, Virginia, 23230
Kaiser Permanente-Riverside
Riverside, California, 92505
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
University of Rochester
Rochester, New York, 14642
Kaiser Permanente-Roseville
Roseville, California, 95661
Kaiser Permanente Downtown Commons
Sacramento, California, 95814
Kaiser Permanente-South Sacramento
Sacramento, California, 95823
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Regions Hospital
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri, 63670
Salina Regional Health Center
Salina, Kansas, 67401
Kaiser Permanente-San Diego Mission
San Diego, California, 92108
Kaiser Permanente-San Diego Zion
San Diego, California, 92120
Kaiser Permanente-San Francisco
San Francisco, California, 94115
Kaiser Permanente-Santa Teresa-San Jose
San Jose, California, 95119
Kaiser Permanente San Leandro
San Leandro, California, 94577
Kaiser Permanente-San Marcos
San Marcos, California, 92078
Kaiser San Rafael-Gallinas
San Rafael, California, 94903
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California, 95051
Kaiser Permanente-Santa Rosa
Santa Rosa, California, 95403
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia, 31405
Prisma Health Cancer Institute - Seneca
Seneca, South Carolina, 29672
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
ThedaCare Cancer Care - Shawano
Shawano, Wisconsin, 54166
LSU Health Sciences Center at Shreveport
Shreveport, Louisiana, 71103
Suburban Hematology Oncology Associates - Snellville
Snellville, Georgia, 30078
Kaiser Permanente-South San Francisco
South San Francisco, California, 94080
Baptist Memorial Hospital and Cancer Center-Desoto
Southhaven, Mississippi, 38671
Spartanburg Medical Center
Spartanburg, South Carolina, 29303
Southern Illinois University School of Medicine
Springfield, Illinois, 62702
Springfield Clinic
Springfield, Illinois, 62702
Springfield Memorial Hospital
Springfield, Illinois, 62781
Missouri Baptist Medical Center
St Louis, Missouri, 63131
Mercy Hospital Saint Louis
St Louis, Missouri, 63141
Lakeview Hospital
Stillwater, Minnesota, 55082
Kaiser Permanente-Stockton
Stockton, California, 95210
Missouri Baptist Sullivan Hospital
Sullivan, Missouri, 63080
BJC Outpatient Center at Sunset Hills
Sunset Hills, Missouri, 63127
Tift Regional Medical Center
Tifton, Georgia, 31794
University of Kansas Health System Saint Francis Campus
Topeka, Kansas, 66606
SMC Center for Hematology Oncology Union
Union, South Carolina, 29379
Carle Cancer Center
Urbana, Illinois, 61801
Kaiser Permanente Medical Center-Vacaville
Vacaville, California, 95688
South Georgia Medical Center/Pearlman Cancer Center
Valdosta, Georgia, 31602
Kaiser Permanente-Vallejo
Vallejo, California, 94589
Ridgeview Medical Center
Waconia, Minnesota, 55387
Kaiser Permanente-Walnut Creek
Walnut Creek, California, 94596
Illinois CancerCare - Washington
Washington, Illinois, 61571
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007
MedStar Washington Hospital Center
Washington D.C., District of Columbia, 20010
ThedaCare Cancer Care - Waupaca
Waupaca, Wisconsin, 54981
Ascension Medical Group Southeast Wisconsin - Mayfair Road
Wauwatosa, Wisconsin, 53226
AdventHealth Infusion Center Weaverville
Weaverville, North Carolina, 28787
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, 66205
Rice Memorial Hospital
Willmar, Minnesota, 56201
Christiana Care Health System-Wilmington Hospital
Wilmington, Delaware, 19801
Minnesota Oncology Hematology PA-Woodbury
Woodbury, Minnesota, 55125
Kaiser Permanente-Woodland Hills
Woodland Hills, California, 91367
University of Michigan Health - West
Wyoming, Michigan, 49519
Fairview Lakes Medical Center
Wyoming, Minnesota, 55092
About this study
Official title: Disparities in Results of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With Anti-PD-1/Anti-PD-L1 Immunotherapy in a Community Oncology Setting
This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.
Read the detailed description
PRIMARY OBJECTIVE:
- To compare incidence of Common Terminology Criteria for Adverse Events (CTCAE) grade 2-5 immune-related adverse reactions (irAEs) between African American (AA) and European American (EA) patients within the first year of starting immune checkpoint inhibitor (ICI) treatment.
SECONDARY OBJECTIVES:
- To compare objective response rate (ORR) to ICI treatment between AA and EA patients within the first year of starting ICI treatment.
II. To compare health-related quality of life (HRQOL) measured using the Patient Reported Outcomes Measurement Information System (PROMIS) Preference (Patient Reported Outcomes [PRO] Pr) summary score and Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM) between AA and EA patients within 1 year of starting ICI treatment.
EXPLORATORY OBJECTIVES:
- To compare AA and EA patients on severity (i.e., CTCAE grade) and timing of irAEs within 1 year of starting ICI treatment.
II. To assess disease, treatment, individual, and behavioral factors as predictors of grade 2-5 irAEs, and as potential causes of racial differences in irAEs, within 1 year of starting ICI treatment.
III. To compare AA and EA patients on long-term outcomes (e.g., progression-free survival [PFS], overall survival [OS], and HRQOL beyond the first year) at the end of the study period.
IV. To assess the impact of irAEs and disease, treatment, behavioral, and individual factors on ICI outcomes (ORR, HRQOL, PFS, OS), and as potential causes of racial differences in outcomes, at the end of the study period.
- To compare ICI treatment patterns (e.g., delay and discontinuation of ICI treatment) between AA and EA patients within 1 year of starting ICI treatment.
VI. To assess irAEs, treatment, disease, and individual factors, including healthcare barriers, as possible reasons for suboptimal treatment patterns, and as potential causes of racial differences, within 1 year of starting ICI treatment.
VII. To collect optional stool samples and an additional blood sample at the time of the occurrence of grade 3-4 irAEs to strengthen the biobank for future research on ICI response and racial disparities.
OUTLINE: This is an observational study.
Patients complete questionnaires and undergo collection of blood, saliva, and optional stool samples before 1st and 2nd infusion of immunotherapy. Patients also complete additional questionnaires undergo additional collection of blood samples 6 months after 1st infusion of immunotherapy and then every year after 1st infusion of immunotherapy. A tumor sample will also be collected at the beginning of the study and patients medical records will be reviewed. Patients may also optionally complete an interview following their 2nd infusion of immunotherapy.
- Being tested
- Biospecimen Collection, Electronic Health Record Review, Interview, Quality-of-Life Assessment, Questionnaire Administration
- Medical subject headings
- Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Biospecimen CollectionProcedure or surgery
Also called Biological Sample Collection, Biospecimen Collected, Specimen Collection
Undergo collection of tumor, blood, saliva and stool samples
Electronic Health Record ReviewOther
Review of medical records
InterviewOther
Complete an interview
Quality-of-Life AssessmentOther
Also called Quality of Life Assessment
Ancillary studies
Questionnaire AdministrationOther
Complete questionnaires
| Study group | Role | What they receive |
|---|---|---|
| Observational (questionnaire, biospecimen, medical records)) | Patients complete questionnaires and undergo collection of blood, saliva and optional stool samples before 1st and 2nd infusion of immunotherapy. Patients also complete additional questionnaires undergo additional collection of blood samples 6 months after 1st infusion of immunotherapy and then every year after 1st infusion of immunotherapy. A tumor sample will also be collected at the beginning of the study and patients medical records will be reviewed. Patients may also optionally complete an interview following their 2nd infusion of immunotherapy. Receives: Procedure: Biospecimen Collection; Other: Electronic Health Record Review; Other: Interview; Other: Quality-of-Life Assessment; Other: Questionnaire Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Racial differences in the incidence of Common Terminology Criteria for Adverse Events (CTCAE) grade 2-5 immune-related adverse reactions (irAEs)
Will be evaluated in bivariate analysis by Chi-square, Wilcoxon rank-sum test, or two sample t-tests.
Measured: Within 1 year after starting immune checkpoint inhibitor (ICI) treatment
Secondary outcomes (3)
Racial differences in overall response rate (ORR) between African American (AA) and European American (EA) patients
Multivariable modeling will be conducted to adjust for covariates.
Measured: Within 1 year after starting ICI treatment
Health-related quality of life (HRQOL) - PROPr
Will be assessed by Patient Reported Outcomes Preference (PROPr). This is a T-score with a mean of 50 and a standard deviation of 0.
Measured: Within 1 year after starting ICI treatment
Health-related quality of life (HRQOL) - FACT-ICM
Will be assessed by Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM), which is a count of symptoms.
Measured: Within 1 year after starting ICI treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2022
- Study start26 Apr 2022
- Primary completion31 Oct 2026 (estimated)
- Study completion31 Jan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematopoietic and Lymphoid Cell NeoplasmStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Rochester NCORP Research Base
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Principal investigator, Charles Kamen, University of Rochester NCORP Research Base
- Investigators
- Charles Kamen, PhD, Principal investigator, University of Rochester NCORP Research Base
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05364086
- Sponsor's protocol ID
- URCC21038
- Other IDs
- NCI-2022-01426, URCC21038, URCC-21038, URCC-21038, UG1CA189961, UH3CA260602
- Acronym
- DiRECT
- Status last verified
- Mar 2026
- First submitted
- 31 Mar 2022
- Last updated
- 13 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 13 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Disparities in Results of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With Anti-PD-1/Anti-PD-L1 Immunotherapy in a Community Oncology Setting
- ClinicalTrials.gov ID
- NCT05364086
- Acronym / sponsor ID
- DiRECT / URCC21038
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 2,100 participants (estimated)
- Lead sponsor
- University of Rochester NCORP Research BaseUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 26 Apr 2022 (actual)
- Primary completion
- 31 Oct 2026 (estimated)
- Study completion
- 31 Jan 2030 (estimated)
- First posted
- 6 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.
Detailed description
PRIMARY OBJECTIVE:
- To compare incidence of Common Terminology Criteria for Adverse Events (CTCAE) grade 2-5 immune-related adverse reactions (irAEs) between African American (AA) and European American (EA) patients within the first year of starting immune checkpoint inhibitor (ICI) treatment.
SECONDARY OBJECTIVES:
- To compare objective response rate (ORR) to ICI treatment between AA and EA patients within the first year of starting ICI treatment.
II. To compare health-related quality of life (HRQOL) measured using the Patient Reported Outcomes Measurement Information System (PROMIS) Preference (Patient Reported Outcomes [PRO] Pr) summary score and Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM) between AA and EA patients within 1 year of starting ICI treatment.
EXPLORATORY OBJECTIVES:
- To compare AA and EA patients on severity (i.e., CTCAE grade) and timing of irAEs within 1 year of starting ICI treatment.
II. To assess disease, treatment, individual, and behavioral factors as predictors of grade 2-5 irAEs, and as potential causes of racial differences in irAEs, within 1 year of starting ICI treatment.
III. To compare AA and EA patients on long-term outcomes (e.g., progression-free survival [PFS], overall survival [OS], and HRQOL beyond the first year) at the end of the study period.
IV. To assess the impact of irAEs and disease, treatment, behavioral, and individual factors on ICI outcomes (ORR, HRQOL, PFS, OS), and as potential causes of racial differences in outcomes, at the end of the study period.
- To compare ICI treatment patterns (e.g., delay and discontinuation of ICI treatment) between AA and EA patients within 1 year of starting ICI treatment.
VI. To assess irAEs, treatment, disease, and individual factors, including healthcare barriers, as possible reasons for suboptimal treatment patterns, and as potential causes of racial differences, within 1 year of starting ICI treatment.
VII. To collect optional stool samples and an additional blood sample at the time of the occurrence of grade 3-4 irAEs to strengthen the biobank for future research on ICI response and racial disparities.
OUTLINE: This is an observational study.
Patients complete questionnaires and undergo collection of blood, saliva, and optional stool samples before 1st and 2nd infusion of immunotherapy. Patients also complete additional questionnaires undergo additional collection of blood samples 6 months after 1st infusion of immunotherapy and then every year after 1st infusion of immunotherapy. A tumor sample will also be collected at the beginning of the study and patients medical records will be reviewed. Patients may also optionally complete an interview following their 2nd infusion of immunotherapy.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observational (questionnaire, biospecimen, medical records)) | – | Procedure: Biospecimen Collection, Other: Electronic Health Record Review, Other: Interview, Other: Quality-of-Life Assessment, Other: Questionnaire AdministrationPatients complete questionnaires and undergo collection of blood, saliva and optional stool samples before 1st and 2nd infusion of immunotherapy. Patients also complete additional questionnaires undergo additional collection of blood samples 6 months after 1st infusion of immunotherapy and then every year after 1st infusion of immunotherapy. A tumor sample will also be collected at the beginning of the study and patients medical records will be reviewed. Patients may also optionally complete an interview following their 2nd infusion of immunotherapy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- African American or European American patients diagnosed with stage I-IV invasive cancer receiving immune checkpoint inhibitor treatment
Key inclusion criteria (8 listed)
- Be 18 years of age or older
- Self-identify as African/African American/black (AA), or European American/ Caucasian/white (EA)
- Have a current diagnosis of invasive cancer at stage I-IV
- Be scheduled to receive anti-PD-1/-L1 ICI-containing therapy alone or in combination with co-treatments (including alternative ICIs)
- Be able to speak and read English or Spanish
Key exclusion criteria (4 listed)
- Identify as Asian, Pacific Islander, or American Indian/Alaskan Native
- Be diagnosed with melanoma (because melanoma is very rare in AAs)
- Currently participate in any trials of a cancer therapeutic nature; participation in noninterventional trial, or trials of symptom control or supportive nature is allowed; participation in future cancer therapeutic trials after completing the A2 assessment (e.g., after the second infusion of ICIs) is also allowed
- Have received prior immunotherapy for cancer, including checkpoint inhibitors, chimeric antigen receptor (CAR)-T therapy, cytokine therapy, and/or Bacillus Calmette-Guerin (BCG) for bladder cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biospecimen CollectionAlso: Biological Sample Collection, Biospecimen Collected, Specimen CollectionUndergo collection of tumor, blood, saliva and stool samples | Procedure or surgery | Observational (questionnaire, biospecimen, medical records)) |
| Electronic Health Record ReviewReview of medical records | Other | Observational (questionnaire, biospecimen, medical records)) |
| InterviewComplete an interview | Other | Observational (questionnaire, biospecimen, medical records)) |
| Quality-of-Life AssessmentAlso: Quality of Life AssessmentAncillary studies | Other | Observational (questionnaire, biospecimen, medical records)) |
| Questionnaire AdministrationComplete questionnaires | Other | Observational (questionnaire, biospecimen, medical records)) |
Primary outcome
Racial differences in the incidence of Common Terminology Criteria for Adverse Events (CTCAE) grade 2-5 immune-related adverse reactions (irAEs)
Time frame: Within 1 year after starting immune checkpoint inhibitor (ICI) treatment
Will be evaluated in bivariate analysis by Chi-square, Wilcoxon rank-sum test, or two sample t-tests.
3 secondary outcomes
Racial differences in overall response rate (ORR) between African American (AA) and European American (EA) patients
Time frame: Within 1 year after starting ICI treatment
Health-related quality of life (HRQOL) - PROPr
Time frame: Within 1 year after starting ICI treatment
Health-related quality of life (HRQOL) - FACT-ICM
Time frame: Within 1 year after starting ICI treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Mar 2026.
Related trials for Hematopoietic and Lymphoid Cell Neoplasm
Not yet recruitingPhase 4
MACE and BTK Inhibitors
Hematologic Cancer, MACE
Recruiting
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Solid Tumor, Adult, Solid Tumor, Childhood
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Active, not recruitingPhase 2
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Charles Kamen, PhD principal investigator
University of Rochester NCORP Research Base
259 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, run by University of Rochester NCORP Research Base at 259 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 13 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 259 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Racial differences in the incidence of Common Terminology Criteria for Adverse Events (CTCAE) grade 2-5 immune-related adverse reactions (irAEs) (time frame: Within 1 year after starting immune checkpoint inhibitor (ICI) treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2026.